#United States #New York #Levi & Korsinsky #class action lawsuit #Unicycive Therapeutics

Important Update on Unicycive Therapeutics Class Action Lawsuit

Levi & Korsinsky, LLP has issued a notification to institutional investors regarding a pending class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This legal notice is particularly crucial for shareholders who purchased Unicycive securities during the defined Class Period, spanning from December 29, 2025, to June 29, 2026. Investors must be aware that the deadline for filing as a lead plaintiff is set for November 2, 2026.

Background of the Class Action

The lawsuit stems from allegations claiming that Unicycive Therapeutics submitted a New Drug Application (NDA) for its oxylanthanum carbonate without conducting a thorough inspection of its third-party manufacturing facility to ensure compliance with current good manufacturing practices (cGMP). This lapse has led to significant questions about the integrity of the information provided and resulted in a stark decline in the company's stock value.

On June 30, 2026, it was announced that UNCY shares had plummeted to $4.69, down significantly from a Class Period high of $8.56 on May 14, 2026. The high volume of trading suggested heightened investor concern, leading to a loss of approximately $3.01 per share—an alarming 39.1% drop.

Implications for Investors

This situation has economic consequences for pension funds, asset managers, and other fiduciaries that held Unicycive shares during this tumultuous period. The lawsuit contends that the shares were sold at artificially inflated prices, indicating the potential for recoverable losses. Executives and individuals associated with Unicycive, as well as the third-party manufacturing vendor involved, are named as defendants in the lawsuit.

Fiduciaries are urged to document and assess their losses arising from the alleged securities violations. Those holding UNCY shares during the Class Period—whether they still own those shares or not—are encouraged to get involved. Appointing a lead plaintiff does not incur any additional costs but allows for a more substantial role in how the lawsuit is navigated in court. Courts typically select the investor with the largest verified loss to serve this function, hence emphasizing the importance of documenting all trading activities.

Critical Deadlines and Next Steps

A critical element for anyone wishing to potentially lead this lawsuit is the deadline for filing, which must occur by November 2, 2026. Those interested should contact Joseph E. Levi, Esq. at Levi & Korsinsky, LLP via email or phone number provided in the notice for guidance on how to assess their eligibility and understand the lead plaintiff process better.

Frequently Asked Questions about the ongoing lawsuit indicate that even if shareholders have sold their stocks, they may still be eligible for recovery based on their purchase history during the Class Period. This includes answering common queries about the court’s jurisdiction, the nature of the lead plaintiff role, and obligations required from class members.

Conclusion

As institutional investors come to terms with market changes and the ramifications of the Unicycive lawsuit, it’s paramount to remain proactive in addressing potential losses and considering options for recovery. The legal landscape is shifting, and understanding every aspect of this case provides a solid footing for informed decision-making in the wake of significant stock volatility.